Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen.

Trial Profile

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2013

At a glance

  • Drugs Fluticasone furoate (Primary) ; Olopatadine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 16 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top